Literature DB >> 22917137

Disclosure of Alzheimer's disease biomarker status in subjects with mild cognitive impairment.

Pieter Jelle Visser, Henrike Wolf, Giovanni Frisoni, Hermann-Josef Gertz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22917137     DOI： 10.2217/bmm.12.58

Source DB:  PubMed          Journal:  Biomark Med        ISSN： 1752-0363            Impact factor:   2.851


× No keyword cloud information.
  10 in total

Review 1.  Review of the Ethical Issues of a Biomarker-Based Diagnoses in the Early Stage of Alzheimer's Disease.

Authors:  Gwendolien Vanderschaeghe; Kris Dierickx; Rik Vandenberghe
Journal:  J Bioeth Inq       Date:  2018-03-12       Impact factor: 1.352

2.  (123)I-FP-CIT SPECT imaging in early diagnosis of dementia in patients with and without a vascular component.

Authors:  Marina Garriga; Marta Milà; Manzoor Mir; Raid Al-Baradie; Sonia Huertas; Cesar Castejon; Laura Casas; Dolors Badenes; Nuria Giménez; M Angels Font; Jose M Gonzalez; Maria Ysamat; Miguel Aguilar; Mark Slevin; Jerzy Krupinski
Journal:  Front Syst Neurosci       Date:  2015-07-01

3.  Biomarker-based diagnosis of mild cognitive impairment due to Alzheimer's disease: how and what to tell. A kickstart to an ethical discussion.

Authors:  Corinna Porteri; Giovanni B Frisoni
Journal:  Front Aging Neurosci       Date:  2014-03-19       Impact factor: 5.750

Review 4.  Personalized health care beyond oncology: new indications for immunoassay-based companion diagnostics.

Authors:  Richard Batrla; Bruce W M Jordan
Journal:  Ann N Y Acad Sci       Date:  2015-04-09       Impact factor: 5.691

5.  Unbiased estimates of cerebrospinal fluid β-amyloid 1-42 cutoffs in a large memory clinic population.

Authors:  Daniela Bertens; Betty M Tijms; Philip Scheltens; Charlotte E Teunissen; Pieter Jelle Visser
Journal:  Alzheimers Res Ther       Date:  2017-02-14       Impact factor: 6.982

6.  ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics.

Authors:  Agnetha D Fruijtier; Leonie N C Visser; Ingrid S van Maurik; Marissa D Zwan; Femke H Bouwman; Wiesje M van der Flier; Ellen M A Smets
Journal:  Alzheimers Res Ther       Date:  2019-08-31       Impact factor: 6.982

7.  What patients want to know, and what we actually tell them: The ABIDE project.

Authors:  Agnetha D Fruijtier; Leonie N C Visser; Femke H Bouwman; Rogier Lutz; Niki Schoonenboom; Kees Kalisvaart; Liesbeth Hempenius; Gerwin Roks; Leo Boelaarts; Jules J Claus; Mariska Kleijer; Marlijn de Beer; Wiesje M van der Flier; Ellen M A Smets
Journal:  Alzheimers Dement (N Y)       Date:  2020-12-16

8.  Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.

Authors:  Gwendolien Vanderschaeghe; Jolien Schaeverbeke; Rose Bruffaerts; Rik Vandenberghe; Kris Dierickx
Journal:  Alzheimers Res Ther       Date:  2017-12-02       Impact factor: 6.982

9.  Perspectives on Communicating Biomarker-Based Assessments of Alzheimer's Disease to Cognitively Healthy Individuals.

Authors:  Richard Milne; Eline Bunnik; Ana Diaz; Edo Richard; Shirlene Badger; Dianne Gove; Jean Georges; Karine Fauria; Jose-Luis Molinuevo; Katie Wells; Craig Ritchie; Carol Brayne
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

10.  Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey.

Authors:  Daniela Bertens; Stephanie Vos; Patrick Kehoe; Henrike Wolf; Flavio Nobili; Alexandre Mendonça; Ineke van Rossum; Jacub Hort; Jose Luis Molinuevo; Michael Heneka; Ron Petersen; Philip Scheltens; Pieter Jelle Visser
Journal:  Alzheimers Res Ther       Date:  2019-08-22       Impact factor: 6.982
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.